NEXT DTP-23-017, PRODUCTION OF 0.25MG OF AZATDC AND TDCYD CAPSULES

Irisys, Inc., San Diego CA

Investigators

Abstract

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) develops cancer therapeutic agents under the Developmental Therapeutics Program (DTP). Part of the DTP services includes formulation and production of clinical dosage forms of the agents selected by DCTD for further development. The Objective of this Task Order is to provide manufacturing of a batch sufficient to deliver 800 capsules containing 0.25 mg Aza-TdC per capsule and 2500 capsules containing 0.25 mg TdCyd per capsule.